FDA
- Status: approved
Intermitent dosing as per SMPC (Intermitent dosing as per SMPC) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Ivan Šitum, MD is the originator. The local marketing authorisation holder may differ — check the official source linked above.